Kindernierenzentrum Bonn

The medical center is at the forefront of research into anemia associated with chronic kidney disease (CKD), focusing on innovative treatments for pediatric patients. The center's work in this area aims to improve the quality of life for children and adolescents suffering from this condition.

• Roxadustat for pediatric anemia

By exploring the pharmacokinetics and pharmacodynamics of new treatments, the center is paving the way for safer and more effective therapies.

Specializing in complement 3 glomerulopathy, the center is dedicated to advancing the understanding and treatment of this rare kidney disorder. Research efforts are focused on reducing proteinuria and improving patient outcomes.

• Iptacopan efficacy and safety

The center's studies aim to demonstrate the superiority of new treatments over existing options, offering hope for better management of this challenging condition.

With a strong emphasis on pediatric chronic kidney disease (CKD), the center is investigating the long-term safety of combining finerenone with ACE inhibitors or angiotensin receptor blockers. This research is crucial for developing safe treatment protocols for young patients.

• Finerenone safety in children

By focusing on the pediatric population, the center is addressing a critical need for age-appropriate therapies in CKD management.

The center is pioneering research in secondary hyperparathyroidism (SHPT) among pediatric patients undergoing hemodialysis. The goal is to evaluate the efficacy of etelcalcetide in managing this condition, which is a common complication of CKD.

• Etelcalcetide efficacy in SHPT

Through these efforts, the center aims to enhance treatment strategies and improve the health outcomes of children affected by SHPT.

Focusing on primary hyperoxaluria, the center is conducting extensive research to evaluate the long-term safety and efficacy of DCR-PHXC for patients with severe renal impairment. This work is vital for developing effective treatments for this rare genetic disorder.

• DCR-PHXC for renal impairment

The center's research is instrumental in advancing therapeutic options and improving the quality of life for individuals with primary hyperoxaluria.